HHS Nominee Azar: Great News For Industry But ACA Reform Will Be Priority
Executive Summary
Insurance practices are a big driver of drug pricing problems, according to Azar, a former Lilly exec who spent six years at HHS under George W. Bush, providing him valuable experience in department operations.
You may also be interested in...
Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices
During Senate Health, Education, Labor and Pensions Committee hearing on the former Eli Lilly executive's nomination for HHS Secretary, Alex Azar said department should consider whether REMS still necessary upon generic entry.
Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices
During Senate Health, Education, Labor and Pensions Committee hearing on the former Eli Lilly executive's nomination for HHS Secretary, Alex Azar said department should consider whether REMS still necessary upon generic entry.
Medicare Price Negotiations: HHS Nominee Suggests Adapting Part D 'Learnings' To Part B
Alex Azar talks about price negotiation in Medicare Part B, whether his biopharma industry ties would influence his decisions as head of HHS, insulin price increases and importation during the first of his confirmation hearings.